Nervgen Pharma Corp (NGENF)

$2.60 +0.14 (5.83%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 87,321
Avg Vol 272,408
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 12%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology
Sector: Healthcare
Phone: 778-731-1711
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
Witzorwitzout1
Witzorwitzout1 Jul. 7 at 4:38 PM
$NGENF survey on what % shorts are paying ? crazy numbers
0 · Reply
DND603
DND603 Jul. 5 at 4:25 PM
$NGENF We were supposed to hear an update on NVG-300 end of Q1. Is it possible they already have some interest from BP that the the update we get will be license/acquisition announcement?
1 · Reply
Gubbeen
Gubbeen Jul. 4 at 3:51 PM
$NGENF As an experiment, I tried having Google's AI, Gemini, perform a 'Deep Search' summary of the "pharmacodynamics of NVG-291". The resulting 18-page document is, in my opinion, a shockingly good summary of the background science, experimental research and clinical trial strategy/early results: https://docs.google.com/document/d/1_l363pWbUkqsYZ1t_zBkvb2ctV-D20If3Kw-vBYh6QY/edit?usp=sharing In particular, it brought to my attention NervGen's use of a diffusion MRI technology (also Canadian!) that can characterize white matter structure/connectivity. I'm sharing the document with public comments enabled, so if you do check it out and find errors, have suggestions or questions, I'll do my best to incorporate/respond to them. (I take a 'we're in this together' approach to many things, science and investing included.) As with anything posted on the internet from some anon, YMMV/DYODD/etc.
4 · Reply
stocktrader12465
stocktrader12465 Jul. 4 at 6:50 AM
$NGENF Just finished listening to Leslie Fuller's trial experience on the Blink of an Eye Podcast. Wow! Feel relieved to be holding a sizable amount of NervGen shares even if they haven't gone anywhere. LOL So much misinformation, gossip that it was hard to decide to trim or increase one's shares. Getting her sense of smell back, crushing her walking records and her body feeling better are extremely bullish signs of what this dug seems to be able to do in just 12 weeks. For those, who haven't listened to it, here is the link: https://open.spotify.com/episode/5K95RB4XrxPTIyVBHn12Ze?si=5e7f353c9de04663
0 · Reply
newsfile_corp
newsfile_corp Jul. 3 at 8:42 PM
https://nfne.ws/257781 $NGENF $NGEN.TSXV @nervgenp #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #OTC #OT
1 · Reply
Gubbeen
Gubbeen Jul. 3 at 6:55 PM
$NGENF Calling on anyone with serious biomedical chops: Our intuitions about medications are biased by the 'exposure heuristic'--the idea that our physiological responses to substances and stimuli are generally proportional to dose x duration, i.e., 'more and longer' tends to increase the magnitude and/or likelihood of effect. Like many rules-of-thumb, this bias is based on a generalization that, while often valid, it glosses over any number of exceptions. I'd like to get a better grip on what factors are at play in exposure to NVG. Understanding the pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) of the NVG peptide seems critical to interpreting the formal results of the trial as well as the informal reports that are trickling in from treated participants and that we can anticipate from those gaining expanded access. Here's the background/analysis framework Gemini worked up: https://g.co/gemini/share/584db4f38e1b
1 · Reply
DM50418
DM50418 Jul. 3 at 6:33 PM
$NGENF Now that we have positive results with nvg-291, I wonder how the U2FP study (Dr Candace Floyd) with our peptide plus estim is going?
0 · Reply
NextGener
NextGener Jul. 3 at 4:44 PM
$NGENF What is the next catalyst? Meeting with FDA?
1 · Reply
Witzorwitzout1
Witzorwitzout1 Jul. 3 at 12:57 PM
$NGENF https://ktla.com/news/local-news/southern-california-lifeguard-suffers-life-altering-spinal-cord-injury-while-on-the-job/
2 · Reply
ReggieTrades
ReggieTrades Jul. 3 at 5:05 AM
$NGENF The sense of smell thing means it works, and that's wild. I'm waiting to hear that someone is going to receive an extended duration of treatment. I really think that's the limitation here.
0 · Reply
Latest News on NGENF
No data available.
Witzorwitzout1
Witzorwitzout1 Jul. 7 at 4:38 PM
$NGENF survey on what % shorts are paying ? crazy numbers
0 · Reply
DND603
DND603 Jul. 5 at 4:25 PM
$NGENF We were supposed to hear an update on NVG-300 end of Q1. Is it possible they already have some interest from BP that the the update we get will be license/acquisition announcement?
1 · Reply
Gubbeen
Gubbeen Jul. 4 at 3:51 PM
$NGENF As an experiment, I tried having Google's AI, Gemini, perform a 'Deep Search' summary of the "pharmacodynamics of NVG-291". The resulting 18-page document is, in my opinion, a shockingly good summary of the background science, experimental research and clinical trial strategy/early results: https://docs.google.com/document/d/1_l363pWbUkqsYZ1t_zBkvb2ctV-D20If3Kw-vBYh6QY/edit?usp=sharing In particular, it brought to my attention NervGen's use of a diffusion MRI technology (also Canadian!) that can characterize white matter structure/connectivity. I'm sharing the document with public comments enabled, so if you do check it out and find errors, have suggestions or questions, I'll do my best to incorporate/respond to them. (I take a 'we're in this together' approach to many things, science and investing included.) As with anything posted on the internet from some anon, YMMV/DYODD/etc.
4 · Reply
stocktrader12465
stocktrader12465 Jul. 4 at 6:50 AM
$NGENF Just finished listening to Leslie Fuller's trial experience on the Blink of an Eye Podcast. Wow! Feel relieved to be holding a sizable amount of NervGen shares even if they haven't gone anywhere. LOL So much misinformation, gossip that it was hard to decide to trim or increase one's shares. Getting her sense of smell back, crushing her walking records and her body feeling better are extremely bullish signs of what this dug seems to be able to do in just 12 weeks. For those, who haven't listened to it, here is the link: https://open.spotify.com/episode/5K95RB4XrxPTIyVBHn12Ze?si=5e7f353c9de04663
0 · Reply
newsfile_corp
newsfile_corp Jul. 3 at 8:42 PM
https://nfne.ws/257781 $NGENF $NGEN.TSXV @nervgenp #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #OTC #OT
1 · Reply
Gubbeen
Gubbeen Jul. 3 at 6:55 PM
$NGENF Calling on anyone with serious biomedical chops: Our intuitions about medications are biased by the 'exposure heuristic'--the idea that our physiological responses to substances and stimuli are generally proportional to dose x duration, i.e., 'more and longer' tends to increase the magnitude and/or likelihood of effect. Like many rules-of-thumb, this bias is based on a generalization that, while often valid, it glosses over any number of exceptions. I'd like to get a better grip on what factors are at play in exposure to NVG. Understanding the pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body) of the NVG peptide seems critical to interpreting the formal results of the trial as well as the informal reports that are trickling in from treated participants and that we can anticipate from those gaining expanded access. Here's the background/analysis framework Gemini worked up: https://g.co/gemini/share/584db4f38e1b
1 · Reply
DM50418
DM50418 Jul. 3 at 6:33 PM
$NGENF Now that we have positive results with nvg-291, I wonder how the U2FP study (Dr Candace Floyd) with our peptide plus estim is going?
0 · Reply
NextGener
NextGener Jul. 3 at 4:44 PM
$NGENF What is the next catalyst? Meeting with FDA?
1 · Reply
Witzorwitzout1
Witzorwitzout1 Jul. 3 at 12:57 PM
$NGENF https://ktla.com/news/local-news/southern-california-lifeguard-suffers-life-altering-spinal-cord-injury-while-on-the-job/
2 · Reply
ReggieTrades
ReggieTrades Jul. 3 at 5:05 AM
$NGENF The sense of smell thing means it works, and that's wild. I'm waiting to hear that someone is going to receive an extended duration of treatment. I really think that's the limitation here.
0 · Reply
rwelsh633
rwelsh633 Jul. 3 at 12:13 AM
$NGENF with former CMO Daniel Mikol becoming VP of Neuroscience Development, at AbbVie, will NervGen get a deal with them? AbbVie has had so many acquisitions and deals lately, here’s a few: Capstan Therapeutics - 2.1 billion Nimble Therapeutics - unknown Aliada Therapeutics - 1.4 billion Cerevel Therapeutics - 8.7 billion Gubria 2.2 billion Xillio 2.1 billion Simcere- 1.055 billion AbbVie has a 360 billion dollar market cap….since 2022 they have spent 20 billion in acquisitions.
5 · Reply
DM50418
DM50418 Jul. 2 at 9:59 PM
$NGENF Yup, it appears to work as designed. Back when the Phase 1 dose trials were progressing in Australia, I posted here wondering if those participants noticed any “benefits” like less brain fog, etc. Surely patients were asked stuff like that in questionnaires….
2 · Reply
cninc
cninc Jul. 2 at 7:09 PM
$NGENF little something to think about in reference to smell from the podcast down below. Little help from Grok Ai Loss of smell, or anosmia, is a well-documented symptom in Alzheimer’s disease (AD) and can serve as an early indicator of the condition. Here’s a concise overview based on available research: Prevalence and Significance: Studies indicate that olfactory dysfunction, including difficulty identifying or detecting odors, is common in AD, affecting up to 90% of patients. It often appears in the early stages, sometimes before cognitive symptoms become prominent, making it a potential biomarker for early diagnosis. Mechanism: The loss of smell is linked to AD pathology in the brain, particularly the accumulation of amyloid-beta plaques and tau tangles in areas like the olfactory bulb and entorhinal cortex, which are critical for processing smells. These regions are among the first affected in AD, explaining why olfactory deficits can precede memory loss.
1 · Reply
kenridge
kenridge Jul. 2 at 6:10 PM
$NGENF https://www.linkedin.com/in/daniel-mikol-md-phd-1a647935?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=android_app
1 · Reply
kenridge
kenridge Jul. 2 at 6:04 PM
$NGENF Dan was poached - VP Neuroscience at Abbvie. His Linkedin profile is updated.
4 · Reply
Boxbcn24
Boxbcn24 Jul. 2 at 5:17 PM
$NGENF no volume, and Who is selling, every day red and the little things that came out are good.. some manipulation?
4 · Reply
rwelsh633
rwelsh633 Jul. 2 at 12:42 PM
$NGENF Blink of an Eye podcast just put out another interview.. https://blinkofaneye.org/blinkofaneyepodcast/
2 · Reply
Lunasicc42
Lunasicc42 Jul. 1 at 9:57 PM
$NGENF does Nervgen have a meeting with the FDA in August?
1 · Reply
Witzorwitzout1
Witzorwitzout1 Jul. 1 at 1:23 PM
$NGENF can't remember off the top of my head, I can dig into it, but was Dan Mikol on board when Brennan was CEO or did Kelly bring him in.
6 · Reply
EBLSA4X
EBLSA4X Jul. 1 at 12:06 PM
$NGENF Dr Mikol has left the company, somewhat abruptly. This happens in biotech; he'll be replaced and our drug development goes on. https://nervgen.com/nervgen-announces-clinical-leadership-transition-as-nvg-291-continues-to-advance-toward-late-stage-development-and-regulatory-milestones/
2 · Reply
newsfile_corp
newsfile_corp Jul. 1 at 11:30 AM
https://nfne.ws/257405 $NGENF $NGEN.TSXV @nervgenp #Chemicals #Pharmaceutical #Biotechnology #HealthCare #Medical #Pharmaceuticals #OTC #OT
2 · Reply
rwelsh633
rwelsh633 Jul. 1 at 2:42 AM
$NGENF If Texas can passed a law to start a clinical trial for Ibogaine… They are signing a law that is leading to an FDA approved drug development clinical trial that will seek approval as a treatment opioid use disorder. They stated that Texas has many veterans that have opioid use orders and can save Texas money. My question is why can’t NervGen contact states that have many disabled people and help fund phase 3 of NervGen trial? Just a thought!
0 · Reply